UnitedHealth Group vs. CVS Health Stock: Which Healthcare Stock Is the Better Buy in 2026?
 |
| UnitedHealth Group vs. CVS Health |
Worldreview1989 - For U.S. investors looking for exposure to healthcare, two of the most interesting large-cap names are UnitedHealth Group (NYSE: UNH) and CVS Health (NYSE: CVS).
Both companies operate in health insurance, healthcare services and pharmacy-related businesses, but their investment profiles are very different. UnitedHealth is primarily a healthcare-services and insurance powerhouse built around UnitedHealthcare and Optum. CVS combines Aetna insurance, Caremark pharmacy-benefit management, retail pharmacies and healthcare services.
The important question for investors is therefore not simply which company is larger, but which stock offers the better combination of earnings growth, financial strength, valuation, cash flow and risk in 2026?
Based on the latest 2026 results, UnitedHealth currently has the stronger earnings-recovery story and business quality, while CVS offers a potentially more attractive turnaround/value proposition but carries greater execution and regulatory risk.
UnitedHealth vs. CVS: Quick Investment Verdict
| Factor | UnitedHealth Group (UNH) | CVS Health (CVS) |
|---|---|---|
| Core business | Health insurance + healthcare services | Insurance + PBM + pharmacies + healthcare |
| 2025 revenue | $447.6B | More than $350B |
| Latest Q2 2026 revenue | ~$112.0B | $106.1B |
| Q2 2026 adjusted EPS | $6.38 | $2.58 |
| 2026 adjusted EPS outlook | $19.50–$20.00 | $7.90–$8.10 |
| Main growth engine | UnitedHealthcare + Optum | Aetna + Caremark + Health Services |
| Key positive | Strong medical-cost improvement | Major earnings recovery |
| Major risk | Medical-cost inflation | PBM pressure, 340B, Medicare costs |
| Financial quality | Higher | Moderate |
| Turnaround potential | Moderate | High |
| Overall 2026 preference | UNH | Higher-risk alternative |
Financial figures are based on the latest available company reports and guidance as of August 2026.
1. What UnitedHealth Group Actually Owns
 |
| UnitedHealth Group |
UnitedHealth is much more than a traditional health insurer.
Its business is divided primarily between UnitedHealthcare and Optum.
UnitedHealthcare provides health insurance and benefits, while Optum operates across healthcare delivery, technology, pharmacy services and related businesses.
In 2025, UnitedHealth generated approximately $447.6 billion in total revenue, up 12% year over year. However, earnings from operations declined substantially to $19.0 billion because of higher medical costs and other pressures.
The company's 2025 segment numbers demonstrate the scale of its ecosystem:
UnitedHealthcare revenue: $344.9 billion
Optum revenue: $270.6 billion
Optum Health revenue: $102.0 billion
Optum Insight revenue: $19.4 billion
Optum Rx revenue: $154.7 billion
Because of intercompany eliminations, these segment revenues cannot simply be added together to calculate consolidated revenue.
This diversification is one of UnitedHealth's biggest investment advantages.
2. CVS Health Has a Different Business Model
CVS is arguably more complicated from an investment perspective.
Its major businesses include:
Aetna — health insurance
Caremark — pharmacy-benefit management
CVS Pharmacy — retail pharmacy
Health Services — healthcare delivery and related services
That gives CVS a unique position across the healthcare value chain.
The strategy can potentially create significant synergies because CVS can connect:
insurance → pharmacy benefits → prescriptions → clinics → healthcare services.
However, the complexity also creates risks.
For example, CVS must simultaneously manage:
insurance medical costs,
pharmacy reimbursement,
PBM regulation,
drug-pricing changes,
Medicare economics,
retail pharmacy margins,
healthcare utilization.
That makes CVS potentially more difficult to evaluate than UnitedHealth.
3. UnitedHealth's 2026 Earnings Recovery Is the Biggest Bullish Signal
UnitedHealth's second-quarter 2026 results materially improved the investment story.
The company reported approximately $112 billion of Q2 revenue, slightly above the same period a year earlier and ahead of Wall Street expectations.
More importantly, adjusted EPS reached $6.38, significantly above analysts' expectations.
The most important number may be the medical-cost ratio.
UnitedHealthcare's medical-cost ratio declined to:
86.7% in Q2 2026
versus:
89.4% in Q2 2025.
A lower ratio is generally positive because it means a smaller percentage of insurance premiums is being consumed by medical costs.
Management attributed the improvement to factors including product design, medical management and better-aligned pricing.
For investors, this is crucial.
UnitedHealth's major problem over the previous period was not a lack of revenue growth. It was the deterioration of profitability.
Therefore, improving medical-cost economics can have a disproportionately large impact on earnings.
4. UnitedHealth Raises Its 2026 Earnings Guidance
UnitedHealth raised its full-year 2026 adjusted EPS outlook to:
$19.50–$20.00 per share
from its previous outlook of more than $18.25.
That represents a significant improvement in management's earnings expectations.
However, investors should not assume that all problems have disappeared.
Medical utilization remains an important industry-wide risk. UnitedHealth has also reduced enrollment in some lower-margin businesses, including Medicare Advantage, as it attempts to improve profitability.
This illustrates an important investment principle:
Revenue growth is not necessarily the objective when margins are under pressure.
For UnitedHealth, management appears increasingly willing to prioritize profitable membership over maximum membership growth.
That could be positive for long-term shareholder returns.
5. CVS Health's 2026 Earnings Recovery Is Also Impressive
 |
| CVS Health |
CVS delivered an unusually strong second quarter.
According to the company's August 5, 2026 earnings release:
Q2 revenue: $106.1 billion
Revenue growth: 7.3%
GAAP diluted EPS: $2.31
Adjusted EPS: $2.58
Year-to-date operating cash flow: $10.6 billion
CVS subsequently raised its 2026 guidance.
The company now expects:
2026 revenue of at least $414 billion
GAAP EPS of $6.84–$7.04
Adjusted EPS of $7.90–$8.10
Operating cash flow of at least $11.5 billion
This is a meaningful improvement from the company's previous guidance.
6. CVS's Aetna Business Is Showing Signs of Stabilization
One of the most important developments for CVS investors is the improvement at Aetna.
In Q2 2026, CVS reported an Aetna medical benefit ratio of approximately 87.4%, compared with 89.9% a year earlier.
Lower medical spending relative to premiums improves insurance profitability.
Reuters noted that the improvement was supported by lower medical costs and government bonus payments associated with highly rated Medicare plans.
This is important because Aetna had been one of the major sources of concern surrounding CVS.
If Aetna continues improving, the company's overall earnings power could increase substantially.
7. But CVS Has a Major Problem: Caremark
Caremark is one of CVS's greatest assets — and simultaneously one of its biggest investment risks.
The PBM industry is undergoing significant changes.
CVS management indicated that Caremark could experience lower client retention as it becomes more conservative in contract pricing.
The company is also facing pressure from changes in drug-pricing economics and government regulation.
Reuters reported that CVS expects some pressure on Caremark profitability in 2027 as the company changes its approach to rebates and faces regulatory pressures.
For investors, this creates an important distinction:
CVS's 2026 earnings may be improving faster than the market's long-term confidence in the business.
That helps explain why the stock reacted negatively despite an impressive Q2 earnings beat.
8. Why American Investors Reacted Negatively to CVS's Strong Earnings
This is where investor psychology becomes important.
CVS delivered:
$2.58 adjusted EPS
against analyst expectations of approximately $1.85.
Revenue reached $106.1 billion, also exceeding expectations.
Normally, such a result would produce a strong rally.
Instead, CVS shares fell sharply after the earnings announcement.
Why?
Because the market is forward-looking.
Investors were concerned about:
2027 earnings growth,
Caremark customer retention,
PBM profitability,
340B drug-pricing pressure,
Medicare reimbursement,
medical-cost inflation.
Reuters reported that CVS's shares fell nearly 6% following the earnings announcement despite the earnings beat and guidance increase.
This is an important lesson for American stock investors:
A stock can fall after beating earnings when investors believe the future is less attractive than the current quarter.
9. Financial Strength Comparison
UnitedHealth
UnitedHealth's 2025 financial statements showed:
Revenue: $447.6B
Operating income: $19.0B
Net income attributable to UnitedHealth shareholders: $12.1B
Operating cash flow: approximately $19.7B
The company entered 2026 with substantial scale and diversified operations.
However, its 2025 operating margin fell dramatically because of elevated medical costs and other factors.
This means investors should monitor whether the 2026 improvement is structural or temporary.
CVS
CVS generated approximately $10.6 billion in operating cash flow during the first half of 2026, and management raised its full-year operating cash-flow guidance to at least $11.5 billion.
Its 2025 annual report showed approximately:
$8.5B cash and cash equivalents
$60.5B long-term debt
$4.1B current portion of long-term debt
$10.6B operating cash flow in 2025
CVS therefore has significant financial resources, but its balance sheet is more heavily leveraged than many investors might prefer.
That matters because higher interest obligations can reduce the flexibility available for:
acquisitions,
dividends,
share repurchases,
debt reduction,
strategic investments.
10. Valuation: UNH vs. CVS
As of the latest August 2026 market data available, UnitedHealth was trading around the high-$300s per share.
The market data showed a market capitalization of approximately $352 billion and a trailing P/E around 25x.
The more useful valuation metric for UnitedHealth, however, may be its forward earnings potential.
Using the midpoint of the 2026 adjusted EPS guidance:
($19.50 + $20.00) / 2 = $19.75
If the market price remains around $389, the implied forward adjusted P/E is roughly:
$389 ÷ $19.75 ≈ 19.7x
That is much more reasonable than the trailing P/E might initially suggest.
For CVS, using the midpoint of management's 2026 adjusted EPS guidance:
($7.90 + $8.10) / 2 = $8.00
If CVS trades near $100, the implied forward adjusted P/E is approximately:
$100 ÷ $8.00 = 12.5x
That is substantially cheaper than UnitedHealth on forward earnings.
Valuation winner: CVS
But there is an important caveat.
Cheap does not automatically mean undervalued.
CVS receives a lower valuation partly because investors are demanding compensation for greater uncertainty surrounding Caremark, Aetna, Medicare and healthcare regulation.
11. Dividend and Capital Return Considerations
UnitedHealth has historically positioned itself as a shareholder-return company through dividends and share repurchases.
CVS also offers income potential and has historically paid a meaningful dividend.
For income-oriented investors, the correct comparison should not simply be dividend yield.
Investors should examine:
Free cash flow → dividend payout → debt reduction → share buybacks.
A company generating large amounts of recurring cash can sustain shareholder returns more comfortably than a company that relies heavily on borrowing.
This gives UnitedHealth an advantage from a balance-sheet-quality perspective, although CVS's improving cash flow could narrow the gap.
12. What American Investors Are Saying Through the Market Reaction
Rather than relying on a handful of anonymous online comments, the most useful "reader/investor sentiment" signal is how U.S. investors and professional analysts reacted to the latest earnings.
UnitedHealth sentiment
The Q2 reaction was broadly positive because investors saw:
dramatically improved medical-cost ratios,
an earnings beat,
higher 2026 guidance,
evidence that management's restructuring is working.
UnitedHealth shares initially surged following the July 2026 report.
CVS sentiment
CVS's Q2 results were also excellent, but investors focused on what could happen in 2027.
The market reaction effectively said:
"The current numbers are good, but prove that the improvement is sustainable."
That is a very different sentiment profile from UnitedHealth.
13. Biggest Risks for UnitedHealth Stock
1. Medical-cost inflation
The biggest risk is that healthcare utilization rises again.
A small deterioration in the medical-cost ratio can have a major impact on earnings because of UnitedHealth's enormous insurance revenue base.
2. Medicare Advantage
Government reimbursement and Medicare Advantage economics remain critical.
3. Regulatory pressure
Healthcare companies operate in one of the most heavily regulated sectors in the U.S.
4. Optum Health profitability
Optum Health experienced significant profitability pressure in 2025, including a reported operating loss of $278 million.
The turnaround here deserves close monitoring.
5. Political risk
Healthcare policy can change dramatically depending on Washington's regulatory and legislative environment.
14. Biggest Risks for CVS Stock
1. Caremark
PBM economics may change significantly as regulators and customers demand greater transparency.
2. 340B
CVS has already indicated that the federal 340B drug-pricing program can create pressure.
3. Medicare costs
Aetna remains highly sensitive to medical utilization and government reimbursement.
4. Debt
CVS's large debt burden limits financial flexibility.
5. Retail pharmacy economics
The retail pharmacy business faces reimbursement pressure, labor costs and changing consumer behavior.
15. Which Company Has Better Growth Potential?
UnitedHealth
UnitedHealth's growth opportunity comes from combining insurance with Optum's healthcare ecosystem.
The theoretical advantage is powerful:
payer + provider + pharmacy + healthcare technology.
If management successfully improves margins, even modest revenue growth could generate significant earnings growth.
CVS
CVS's growth opportunity is more of a turnaround.
If:
Aetna margins improve,
Caremark remains profitable,
pharmacy operations stabilize,
healthcare services grow,
debt declines,
then CVS could experience significant earnings expansion.
That gives CVS potentially greater re-rating upside.
16. Which Stock Is Safer?
UnitedHealth.
UnitedHealth has:
greater scale,
broader healthcare infrastructure,
stronger diversification,
a large Optum ecosystem,
significant cash-generation capability.
But "safer" does not mean risk-free.
UnitedHealth experienced a significant earnings deterioration in 2025, demonstrating how quickly healthcare utilization can affect profitability.
17. Which Stock Is More Undervalued?
CVS appears cheaper based on forward earnings.
Using approximate 2026 guidance:
UNH
~$389 share price ÷ ~$19.75 adjusted EPS
= ~19.7x forward P/E
CVS
~$100 share price ÷ ~$8.00 adjusted EPS
= ~12.5x forward P/E
The difference is substantial.
However, CVS deserves some valuation discount because investors are uncertain about the sustainability of its earnings recovery.
18. Which Stock Would I Prefer?
For a long-term investor seeking business quality and earnings visibility, I would currently favor:
UnitedHealth Group (UNH)
The strongest argument is not simply its size.
It is the evidence that profitability is beginning to recover.
The Q2 2026 medical-cost ratio of 86.7%, combined with adjusted EPS of $6.38 and higher full-year guidance, represents a meaningful improvement in the investment thesis.
However, CVS is more interesting for investors willing to accept higher risk.
CVS is the higher-risk value/turnaround play.
If Aetna continues improving and Caremark remains financially resilient, the valuation gap could narrow.
19. UNH vs. CVS: Final Scorecard
| Category | Winner |
|---|---|
| Business quality | UNH |
| Diversification | UNH |
| Balance-sheet quality | UNH |
| Earnings momentum | UNH |
| Forward valuation | CVS |
| Turnaround potential | CVS |
| Dividend/income potential | CVS / Close |
| Healthcare ecosystem | UNH |
| Regulatory simplicity | Neither |
| Risk-adjusted long-term appeal | UNH |
| Speculative value opportunity | CVS |
20. Investment Conclusion
The UnitedHealth vs. CVS debate in 2026 is essentially a battle between quality recovery and value turnaround.
UnitedHealth Group currently has the stronger investment case for investors who prioritize business quality, diversification and improving profitability.
Its 2026 recovery is particularly encouraging because management has improved the medical-cost ratio while simultaneously raising earnings guidance. The company expects adjusted EPS of $19.50–$20.00 for 2026.
CVS Health, meanwhile, offers a cheaper valuation and potentially greater upside if its turnaround continues. Q2 2026 was a strong quarter, with $106.1 billion in revenue and $2.58 adjusted EPS, while management raised its full-year adjusted EPS outlook to $7.90–$8.10.
The problem is that investors are already looking beyond 2026 toward Caremark's profitability, 340B pressures and Medicare economics.
My 2026 ranking:
1. UNH — Best overall risk/reward
2. CVS — Best value/turnaround candidate
For a conservative long-term portfolio, UNH would be my preferred stock.
For an investor specifically looking for a discounted healthcare turnaround, CVS deserves closer attention.
Neither stock should be purchased solely because its P/E ratio looks cheap. Investors should monitor quarterly medical-cost ratios, membership trends, operating cash flow, debt reduction, Medicare economics and management's forward guidance.
This article is educational and not individualized investment advice. Investors should review SEC filings, company earnings releases and their own risk tolerance before buying either stock.
Primary Sources & References
UnitedHealth Group — 2025 Form 10-K, SEC: consolidated revenue, operating income, net income and segment financial data.
UnitedHealth Group — 2025 Fourth-Quarter/FY Earnings Release, SEC: 2026 outlook and 2025 operating performance.
CVS Health — 2025 Form 10-K, SEC: cash flow, debt, liquidity and financial statements.
CVS Health — Q2 2026 Earnings Release: revenue, EPS, cash flow and updated 2026 guidance.
Reuters — August 5, 2026: market reaction to CVS's Q2 results and 2027 outlook.
MarketWatch — July 16, 2026: UnitedHealth Q2 results, medical-cost ratio and raised 2026 guidance.
Barron's — July 16, 2026: UnitedHealth Q2 earnings and medical-cost improvement.
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group